Literature DB >> 15888786

Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease.

K Yamamoto1, T Kiyohara, Y Murayama, S Kihara, Y Okamoto, T Funahashi, T Ito, R Nezu, S Tsutsui, J-I Miyagawa, S Tamura, Y Matsuzawa, I Shimomura, Y Shinomura.   

Abstract

BACKGROUND AND AIMS: A characteristic feature of Crohn's disease (CD) is mesenteric adipose tissue hypertrophy. Mesenteric adipocytes or specific proteins secreted by them may play a role in the pathogenesis of CD. We recently identified adiponectin as an adipocyte specific protein with anti-inflammatory properties. Here we report on expression of adiponectin in mesenteric adipose tissue of CD patients. METHODS AND
RESULTS: Mesenteric adipose tissue specimens were obtained from patients with CD (n = 22), ulcerative colitis (UC) (n = 8) and, for controls, colon carcinoma patients (n = 28) who underwent intestinal resection. Adiponectin concentrations were determined by enzyme linked immunosorbent assay, and adiponectin mRNA levels were determined by real time quantitative reverse transcription-polymerase chain reaction. Tissue concentrations and release of adiponectin were significantly increased in hypertrophied mesenteric adipose tissue of CD patients compared with normal mesenteric adipose tissue of CD patients (p = 0.002, p = 0.040, respectively), UC patients (p = 0.002, p = 0.003), and controls (p<0.0001, p<0.0001). Adiponectin mRNA levels were significantly higher in hypertrophied mesenteric adipose tissue of CD patients than in paired normal mesenteric adipose tissue from the same subjects (p = 0.024). Adiponectin concentrations in hypertrophied mesenteric adipose tissue of CD patients with an internal fistula were significantly lower than those of CD patients without an internal fistula (p = 0.003).
CONCLUSIONS: Our results suggest that adipocytes in hypertrophied mesenteric adipose tissue produce and secrete significant amounts of adiponectin, which could be involved in the regulation of intestinal inflammation associated with CD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888786      PMCID: PMC1774527          DOI: 10.1136/gut.2004.046516

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  40 in total

1.  Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro.

Authors:  C P Sewter; J E Digby; F Blows; J Prins; S O'Rahilly
Journal:  J Endocrinol       Date:  1999-10       Impact factor: 4.286

2.  Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.

Authors:  N Ouchi; S Kihara; Y Arita; M Nishida; A Matsuyama; Y Okamoto; M Ishigami; H Kuriyama; K Kishida; H Nishizawa; K Hotta; M Muraguchi; Y Ohmoto; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  2001-02-27       Impact factor: 29.690

3.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.

Authors:  N Maeda; M Takahashi; T Funahashi; S Kihara; H Nishizawa; K Kishida; H Nagaretani; M Matsuda; R Komuro; N Ouchi; H Kuriyama; K Hotta; T Nakamura; I Shimomura; Y Matsuzawa
Journal:  Diabetes       Date:  2001-09       Impact factor: 9.461

4.  Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.

Authors:  N Ouchi; S Kihara; Y Arita; Y Okamoto; K Maeda; H Kuriyama; K Hotta; M Nishida; M Takahashi; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

5.  Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

Authors:  Terry P Combs; John A Wagner; Joel Berger; Tom Doebber; Wen-Jun Wang; Bei B Zhang; Michael Tanen; Anders H Berg; Stephen O'Rahilly; David B Savage; Krishna Chatterjee; Stuart Weiss; Patrick J Larson; Keith M Gottesdiener; Barry J Gertz; Maureen J Charron; Philipp E Scherer; David E Moller
Journal:  Endocrinology       Date:  2002-03       Impact factor: 4.736

6.  The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance.

Authors:  T Yamauchi; J Kamon; H Waki; K Murakami; K Motojima; K Komeda; T Ide; N Kubota; Y Terauchi; K Tobe; H Miki; A Tsuchida; Y Akanuma; R Nagai; S Kimura; T Kadowaki
Journal:  J Biol Chem       Date:  2001-08-31       Impact factor: 5.157

7.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages.

Authors:  T Yokota; K Oritani; I Takahashi; J Ishikawa; A Matsuyama; N Ouchi; S Kihara; T Funahashi; A J Tenner; Y Tomiyama; Y Matsuzawa
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

8.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.

Authors:  N Ouchi; S Kihara; Y Arita; K Maeda; H Kuriyama; Y Okamoto; K Hotta; M Nishida; M Takahashi; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa
Journal:  Circulation       Date:  1999 Dec 21-28       Impact factor: 29.690

9.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

10.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.

Authors:  T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

View more
  73 in total

Review 1.  Adipose tissue and inflammatory bowel disease pathogenesis.

Authors:  Christopher Fink; Iordanes Karagiannides; Kyriaki Bakirtzi; Charalabos Pothoulakis
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

2.  Creeping fat in Crohn's disease: travelling in a creeper lane of research?

Authors:  A Schäffler; H Herfarth
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 3.  Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

Authors:  Laurent Peyrin-Biroulet; Mathias Chamaillard; Florent Gonzalez; Elodie Beclin; Cecilia Decourcelle; Laurent Antunes; Jérôme Gay; Christel Neut; Jean-Frédéric Colombel; Pierre Desreumaux
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

4.  Study of adiponectin in chronic liver disease and cholestasis.

Authors:  Tary A Salman; Naglaa Allam; Gasser I Azab; Ahmed A Shaarawy; Mona M Hassouna; Omkolsoum M El-Haddad
Journal:  Hepatol Int       Date:  2010-10-09       Impact factor: 6.047

Review 5.  Extraluminal factors contributing to inflammatory bowel disease.

Authors:  Arvind Batra; Thorsten Stroh; Britta Siegmund
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

6.  'Nodophagy': New crossroads in Crohn disease pathogenesis.

Authors:  Mahendrasingh Ramjeet; Séamus Hussey; Dana J Philpott; Leonardo H Travassos
Journal:  Gut Microbes       Date:  2010-08-08

7.  Toll-like receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease.

Authors:  Raquel F Leal; Marciane Milanski; Maria de Lourdes S Ayrizono; Andressa Coope; Viviane S Rodrigues; Mariana Portovedo; Luiza M F Oliveira; João J Fagundes; Cláudio S R Coy; Lício A Velloso
Journal:  Int J Clin Exp Med       Date:  2013-01-26

Review 8.  Neuropeptides, mesenteric fat, and intestinal inflammation.

Authors:  Iordanes Karagiannides; Charalabos Pothoulakis
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Adiponectin deficiency does not affect development and progression of spontaneous colitis in IL-10 knockout mice.

Authors:  Maria Pini; Melissa E Gove; Raja Fayad; Robert J Cabay; Giamila Fantuzzi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-12       Impact factor: 4.052

Review 10.  Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease?

Authors:  Ellen S Pierce
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.